Monocyte chemoattractant protein-1 (MCP-1) is a potent chemokine that plays an important role in the recruitment of macrophages. Although previous studies have demonstrated the importance of MCP-1 in the pathogenesis of diabetic nephropathy (DN) in terms of inflammation, the role of MCP-1 and its receptor (C-C chemokine receptor 2; CCR2) on extracellular matrix (ECM) accumulation under diabetic conditions has been largely unexplored. This study was undertaken to investigate the functional role of the MCP-1/CCR2 system on high glucose-induced ECM (fibronectin and type IV collagen) protein expression in cultured mesangial cells (MCs). Mouse MCs were exposed to medium containing 5.6mM glucose (NG), NG+24.4mM mannitol (NG+M), or 30mM glucose (HG) with or without mutant MCP-1 (mMCP-1), CCR2 siRNA, or CCR2 inhibitor (RS102895). To examine the relationship between MCP-1 and TGF-1, MCs were also treated with TGF-1 (2ng/ml) with or without mMCP-1 or CCR2 siRNA. Transient transfection was performed with Lipofectamine 2000 for 24 hours. Cell viability was determined by an MTT assay, mouse and human MCP-1 and TGF-1 levels by ELISA, and CCR2 and ECM protein expression by Western blot. Transfections of mMCP-1 and CCR2 siRNA increased human MCP-1 levels and inhibited CCR2 expression, respectively. HG-induced ECM protein expression and TGF-1 levels were significantly attenuated by mMCP-1, CCR2 siRNA, and RS102895 (p<0.05). MCP-1 directly increased ECM protein expression and this increase was inhibited by an anti-TGF-1 antibody. In addition, TGF-1-induced ECM protein expression was significantly abrogated by the inhibition of the MCP-1/CCR2 system (p<0.05). These results suggest that an interaction between the MCP-1/CCR2 system and TGF-1 may contribute to ECM accumulation in DN.
Introduction
Monocytes/macrophages are the principle inflammatory cells found in diabetic kidney (6, 9, 29) . These cells are extravasculated from the bloodstream through a process mediated by chemokines secreted from resident glomerular cells. Chemokines are a family of chemotactic cytokines that induce the migration of various cell types and to date more than 40 chemokines have been identified (31) . Among them, monocyte chemoattractant protein (MCP)-1 is the most extensively studied chemokine. In the kidney, MCP-1 is expressed in mesangial cells and tubular epithelial cells (22, 26) and is known to be involved in the pathogenesis of various renal diseases, including diabetic nephropathy. Previous studies have demonstrated that plasma MCP-1 levels are increased in type 1 diabetes with microalbuminuria (4) and that urinary levels of MCP-1 are also increased in accordance with the extent of albuminuria (1, 20) . In addition, it has been reported that glomerular MCP-1 expression is increased in experimental diabetic rats and that this increase is associated with the number of infiltrated monocytes in the glomeruli (5, 6) . Moreover, angiotensin-converting enzyme inhibitor, angiotensin II type 1 receptor blocker, and aldosterone antagonist all ameliorate glomerular injury in experimental diabetic animals via the inhibition of MCP-1 expression and macrophage infiltration (13, 17) . Taken together, these findings suggest that MCP-1 plays a critical role in the pathogenesis of diabetic glomerulopathy via inducing inflammatory cells infiltration.
On the other hand, several studies have demonstrated that cultured mesangial cells express C-C chemokine receptor2 (CCR2) (10, 16) , a receptor of MCP-1, suggesting that MCP-1 may act directly on these renal cells. Recently, Giunti et al (10) has shown that MCP-1 induces concentration-dependent ICAM-1 expression in cultured mesangial cells, implying that MCP-1 may further increase the inflammatory response by increasing adhesion molecule expression. In addition, some investigators have provided evidences that MCP-1 may be directly involved in extracellular matrix (ECM) synthesis using animal models of experimental glomerulonephritis and diabetic nephropathy (11, 30, 36) . To our knowledge, however, there has been no study that has looked at the functional role of the MCP-1/CCR2 system in high glucose-induced ECM protein expression. In this study, we investigated the role of the MCP-1/CCR2 system in high glucose-induced fibronectin and type IV collagen expression and the relationship between the MCP-1/CCR2 and TGF-1 systems in cultured 
Materials & Methods

Cell cultures
Mouse mesangial cells (MCs) from an SV40 transgenic mouse (MES-13) were purchased from American Type Culture Collection (Manassas, VA, USA) and maintained in Dulbeco's Modified Eagle's Medium (DMEM) (Invitrogen, Gaithersberg, MD, USA) containing 5% fetal bovine serum (FBS) (Invitrogen). MCs were maintained and incubated at 37°C in humidified 5% CO 2 in air.
Inhibition of the MCP-1/CCR2 system
In this study, three different methods were utilized to block the MCP-1/CCR2 system in cultured MCs. First, mutant MCP-1 (mMCP-1) was used to competitively inhibit native MCP-1 action. The mMCP-1 gene was constructed by a recombinant polymerase chain reaction (PCR) using a wild-type human MCP-1 cDNA from human peritoneal mesothelial cells as template, which was then cloned into the BamHI (5') and XhoI (3') sites of the eukaryotic expression vector plasmid cDNA3 (Invitrogen) as described previously (40) .
Second, pre-designed mouse CCR2 siRNA was purchased from Ambion (Austin, TX, USA).
The mMCP-1 gene and CCR2 siRNA were transfected with Lipofectamine 2000 (Invitrogen) according to the manufacturer's protocol. Briefly, 6 µl of Lipofectamine 2000 was diluted in 1 ml of Opti-MEM ® I Reduced Serum Medium (Invitrogen), incubated for 15 minutes at room temperature, and mixed with variable amount of mMCP-1 (final concentrations: 0.5 and 1.0 µg/ml) and CCR2 siRNA (final concentrations: 10, 25, and 50 nM). After 15-minutes incubation at room temperature, the mixture was added to each well of MCs, which were plated at a density of 5 x 10 5 cells/well into 6-well plates the day before, and the medium was changed after 24 hours. Lastly, RS102895 (Sigma Chemical Co., St Louis, MO, USA) (final concentrations: 1 and 10 µM), a specific chemical inhibitor of CCR2, was also used.
Transfected MCs were serum restricted for 24 hours, after which the medium was replaced by serum-free DMEM containing normal glucose (5.6 mM, NG), NG+mannitol µg/ml). Non-transfected MCs were also exposed to medium containing recombinant human MCP-1 (10 ng/ml) (R&D Systems, Minneapolis, MN, USA) or recombinant human TGF-1 (2 ng/ml) (R&D Systems). At 24 hours after the media change, cells were harvested and the conditioned culture media were collected.
Methylthiazoletetrazolium (MTT) assay
To examine the cytotoxicity of the agents used in this study, MCs were cultured in 96-well culture plate, phenol red-free DMEM with 1 mg/ml of MTT added to each well after the experimental periods, and then incubated for 2 hours at 37°C in humidified 5% CO2 in air.
Extraction buffer [20% sodium dodecyl sulfate (SDS), 50% N,N-dimethylformamide, pH 4.7] was added to the wells, which were further incubated overnight at 37°C. Optical density (OD)
was measured with a microplate reader (SpectraMax 340, Molecular Devices Co., CA, USA)
at a wavelength of 562 nm. The OD of the NG cells was assigned a relative value of 100. The experiments were performed in triplicate.
ELISA
The levels of secreted MCP-1 and TGF-1 under different experimental conditions were determined with conditioned culture media using commercial ELISA kits (R&D Systems)
according to the manufacturer's protocol and each protein levels were normalized with cell numbers. The experiments were performed in triplicate.
The kits for mouse and human MCP-1 were species-specific and sensitive up to 2.0 pg/ml and 5.0 pg/ml, respectively. On the other hand, the minimum sensitivity for mouse TGF-1 of the kit used in this study was 4.6 pg/ml.
Western blot analysis
Harvested MCs lysed in SDS sample buffer [2% SDS, 10 mM Tris-HCl, pH 6.8, 10%
(vol/vol) glycerol] were used for CCR2, fibronectin, and type IV collagen protein expression.
The samples were treated with Laemmli sample buffer, heated at 100°C for 5 minutes, and electrophoresed in a 10% acrylamide denaturing SDS-polyacrylamide gel. Proteins were then transferred to a Hybond-ECL membrane using a Hoeffer semidry blotting apparatus (Hoeffer Instruments, San Francisco, CA). The membrane was then incubated in blocking buffer A (1 x PBS, 0.1% Tween-20, and 8% nonfat milk) for 1 hour at room temperature, followed by an 
Statistical analysis
All values are expressed as the mean ± standard error of the mean (SEM). Statistical analysis was performed using the statistical package SPSS for Windows Ver. 11.0 (SPSS, Inc., Chicago, IL). Results were analyzed using the Kruskal-Wallis non-parametric test for multiple comparisons. Significant differences by the Kruskal-Wallis test were further confirmed by the Mann-Whitney U test. P values less than 0.05 were considered statistically significant.
Results
MCP-1 and CCR2 levels in mMCP-1 and CCR2 siRNA-transfected MCs
The levels of mouse and human MCP-1 were measured in transfected MCs with different concentrations of mMCP-1 (0.5 or 1 µg/ml) to evaluate transfection efficiency. Human MCP-
The concentrations of mMCP-1 (0.5 and 1 µg/ml), CCR2 siRNA (10 and 50 nM), and RS102895 (1 and 10 µM) used in this study did not affect cell viability, which was assessed by an MTT assay (data not shown).
MCP-1/CCR2 inhibition ameliorates HG-induced fibronection and type IV collagen expression
To clarify whether the MCP-1/CCR2 system is involved in HG-induced ECM protein expression, we first examined the effects of MCP-1 on fibronectin and type IV collagen (Fig. 3D ).
MCP-1/CCR2 inhibition ameliorates HG-induced TGF-1 levels
Since TGF-1 is the most well-known profibrogenic cytokine and its expression is increased under diabetic conditions, we attempted to elucidate whether the MCP-1/CCR2 system was involved in HG-induced TGF-1 levels. First, the direct effects of MCP-1 on TGF-1 levels were examined. The administration of 10 ng/ml MCP-1 in MCs significantly increased the levels of TGF-1 in conditioned media (p<0.05), and this increase in TGF-1 concentrations was significantly abrogated by the inhibition of CCR2 with 10 nM CCR2 siRNA or 10 µM RS102895 (Fig. 4A) , suggesting that MCP-1 directly induced TGF-1 levels in MCs via CCR2. Next, we evaluated the role of the MCP-1/CCR2 system in HGinduced TGF-1 levels. Compared to MCs exposed to NG, the concentrations of TGF-1 in conditioned media was significantly increased in HG-stimulated MCs (2068 ± 104 vs. 2955 ±
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239 pg/10 6 cells, p<0.05), and this increase in TGF-1 levels was significantly attenuated by the administration of 0.5 µg/ml mMCP-1, 10 nM CCR2 siRNA, and 10 µM RS102895 (Fig.   4B ).
MCP-1/CCR2 inhibition ameliorates TGF-1-induced fibronectin and type IV collagen expression
The administration of 2 ng/ml TGF-1 significantly increased the protein expression of fibronectin and type IV collagen in cultured MCs (p<0.05), which was significantly abrogated by the inhibition of the MCP-1/CCR2 system with 0.5 µg/ml mMCP-1, 10 nM CCR2 siRNA, and 10 µM RS102895 (p<0.05) (Fig. 5) .
MCP-1 and TGF-1 do not exert additive effect on fibronectin and type IV collagen expression
The administration of 10 ng/ml MCP-1 or 2 ng/ml TGF-1 significantly increased fibronectin and type IV collagen expression in cultured MCs (p<0.05), but the addition of TGF-1 to MCP-1 did not show any additive or synergistic effect on ECM protein expression (Fig. 6 ).
TGF-1 inhibition ameliorates HG-induced MCP-1 levels
The levels of MCP-1 in HG-conditioned media were significantly increased by 142.6% compared to NG media, and this increase in MCP-1 levels was significantly abrogated by treatment with TGF-1 neutralizing antibody (p<0.05) (Fig. 7) .
TGF-1 inhibition ameliorates MCP-1-induced fibronectin and type IV collagen expression
The administration of 10 ng/ml MCP-1 significantly increased the protein expression of fibronectin and type IV collagen in cultured MCs (p<0.05), and this increase in ECM protein expression was significantly abrogated by treatment with TGF-1 neutralizing antibody (p<0.05) (Fig. 8) .
Discussion
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A recent study has provided evidence that MCP-1 is directly involved in ECM synthesis using a mouse model of experimental diabetic nephropathy and cultured human mesangial cells (11) . However, the role of MCP-1/CCR2 system in high glucose-induced fibronectin and type IV collagen expression has never been explored. In this study, we demonstrate for the previous studies have demonstrated that functional differences exist between the two isoforms and that the two isoforms are expressed by different cell subsets in idiopathic inflammatory myopathies (2, 28) . Based on these findings, there is a possibility that CCR2A and CCR2B may have a different role in the pathogenesis of human diabetic nephropathy, but we could not verify it because mouse MCs were used in this study.
TGF-1 is a well-known mediator of ECM accumulation in diabetic nephropathy (14) . The levels of MCP-1 in HG-conditioned media were significantly increased compared to those in NG media, and this increase in MCP-1 levels was significantly abrogated by treatment with TGF-1 neutralizing antibody. *; p<0.05 vs. Other groups. 
